Physician profile
Jonathan Navar
NPI 1104206697
$1,496.71
in general payments reported to CMS, 2019-2025
11 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $103 · 2021: $14.21 · 2022: $491 · 2023: $21.45 · 2024: $55.51 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $441.28 | 2022-2025 | Breztri |
| Novo Nordisk INC | $347.67 | 2019-2025 | Rybelsus, Wegovy, Ozempic |
| Abbott Laboratories | $207.08 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $171.55 | 2022 | |
| Amgen INC. | $125.00 | 2019 | |
| Edwards Lifesciences Corporation | $73.39 | 2019 | |
| Novartis Pharmaceuticals Corporation | $68.86 | 2020 | |
| Exact Sciences Corporation | $18.06 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $15.11 | 2020 | |
| Lantheus Medical Imaging, INC. | $14.50 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Navar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.